Vera Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

VERA$30.03-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets (unaudited)

Condensed Consolidated Balance Sheets

(in thousands, except share amounts)

	September 30,	December 31,
	2026	2025
Assets
Current assets:
Cash and cash equivalents	$55,322	$354,725
Marketable securities	328,720	359,864
Accounts receivable, net	11,981	—
Inventory	7,078	—
Prepaid expenses and other assets, current	38,184	14,294
Total current assets	441,285	728,883
Intangible assets, net	20,499	—
Other assets, noncurrent	3,968	5,850
Total assets	$465,752	$734,733
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$20,173	$21,898
Accrued expenses and other liabilities, current	35,602	31,557
Total current liabilities	55,775	53,455
Long-term debt	75,434	74,838
Other liabilities, noncurrent	1,357	1,919
Total liabilities	132,566	130,212
Stockholders’ equity
Class A common stock, $0.001 par value; 500,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 72,287,904 and 71,267,429 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	72	71
Additional paid-in capital	1,418,899	1,364,529
Accumulated other comprehensive (loss) income	(704)	786
Accumulated deficit	(1,085,081)	(760,865)
Total stockholders’ equity	333,186	604,521
Total liabilities and stockholders’ equity	$465,752	$734,733

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.